- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01758471
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
An Open-label, Randomized , Phase 4 Study to Compare the Different Efficacies of α-glucosidase Inhibitor and Sulfonylurea on Improvement of Intestinal Microbiome and Serum Incretins in Patients With Type 2 Diabetes
Study Overview
Detailed Description
In recent years, Endocrinologist and Diabetologists have found that intestine might serve as a novel target for treating diabetes or other metabolic diseases. Incretins are well-known hormones secreted from intestine, such as CCK(Cholecystokinin), Serotonin, GIP(gastric inhibitory polypeptide) and GLP-1(glucagon like peptide 1), to help control wholesome metabolic status through their effects on pancreatic islet cells, hypothalamus neurons and gastrointestinal movement. Gut microbiome has been recently revealed exerting major effect on host's immune system and metabolic balance with its various metabolites and components.
α-glucosidase inhibitors have been used as anti-diabetes medicine for dozens of years. They are known to be effective by delaying glucose absorption in small intestine. Questions then have been arisen that if delaying glucose absorption changes the intestinal bacteria flora component by increasing bacteria fed on glucose, or that if it influences incretin secretion, since most glucose sensitive L cell (secreting GLP-1) were located in the distal part of small intestine and colon, and that if the hypoglycemia effect of α-glucosidase inhibitors might be mediated by either intestinal flora or incretins.
To address the questions above and to find the new targets from the intestine to treat diabetes, we therefore design this study, taking advantage of clinical trial and basic biomedical studies to find if α-glucosidase inhibitor- Acarbose (Bayer, Corp.) could change the profile of intestinal incretins and microbiome.
Study design:
- Multi-center, open label, randomized, positive control cohort.
- 110 cases of newly-diagnosed Type-2 Diabetes patients from five clinic centers from Shanghai, China Mainland.
- All patients will sign the consent and screened by the criteria before enrolled by this study.
- 55 cases of Type 2 Diabetes will be assigned to glucobay treatment and another 55 will take glipizide.
- 50 healthy volunteers for baseline data comparison.
The duration of whole study will be 3 month.
- Before treatment, all the patients will be required to have OGTT(oral glucose tolerant test) and IRT(insulin release test) test and give their feces. Standard meals will be required one day before the feces are collected.
- In 3 months, all patients will take the medicine and their glucose will be monitored closely by visiting outpatient office once a month.
- In the end of the study, patients will be required to receive OGTT and IRT and give their feces again.
- Serum and feces will be stored at -80℃ for further biomarkers investigation and microbiome sequencing.
- After 3 months intervention, patients will be observed for another 3 month with access to routine clinic visiting.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Guang Ning, M.D. Ph.D.
- Phone Number: 665344 86-021-64370045
- Email: guangning@medmail.com.cn
Study Contact Backup
- Name: Yanyun Gu, M.D. Ph.D.
- Phone Number: 663325 86-021-64370045
- Email: guyanyun@hotmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Shanghai Clinic Center for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Institute for Endocrine and Metabolic Diseases
-
Contact:
- Guang Ning, M.D.
- Phone Number: 665344 86-021-64370045
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosed Type 2 Diabetes, without any previous drug treatment,
- 7.0 mmol/l <=FBG<=13.O mmol/l, HbA1C <=10%
- Body mass index (BMI) < 35kg/m2 (inclusive);
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted
- Having good study compliance
Exclusion Criteria:
- Intestinal surgery or recent abdominal surgery within 1 year
- Taken immunosuppressive agents, steroid,antidiarrhea agents, antibiotics and other gastrointestinal motility agents within 3 months
- Severe liver dysfunction, including serum alanine aminotransferase concentration more than 2.5 times above upper limit of normal range, abnormal renal function (GFR < 60ml/min)
- Other severe conditions which will put the patients in high risk during the study
- Any clinically significant allergic disease
- Women in pregnancy or under breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acarbose
The minimum dosage of acarbose in this study is 100mg tid p.o.(oral) for 3 month.
With this dosage, patients should have similar glycemic control with those using glipizide, that is FBG(fasting blood glucose)<7.0,PBG(postprandial
blood glucose)<10.0
|
Acarbose 50mg per pill 100mg to 150mgtid p.o.(oral) for 3 month
Other Names:
|
Active Comparator: glipizide
There is no fixed dosage of glipizide to control hyperglycemia for patients in this group.
As long as the targeted blood glucose concentration is reached, FBG< 7.0, PBG< 10.0, patients will have the least dosage of glipizide according to their glucose level.
|
glipizide 5mg per pill 5mg tid p.o. for 3 month
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
euglycemia
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Guang Ning, M.D. Ph.D., Shanghai Jiao Tong University School of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCEMD017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Acarbose
-
EMSCompletedType 2 Diabetes MellitusBrazil
-
BayerCompletedDiabetes Mellitus, Type 2Germany
-
BayerCompletedDiabetes Mellitus, Type 2Germany
-
BayerCompleted
-
Guiyang Medical UniversityNot yet recruitingHead and Neck Squamous CarcinomaChina
-
Radboud University Medical CenterCompletedType 2 Diabetes | Endothelial DysfunctionNetherlands
-
The Cleveland ClinicCompleted
-
The University of Texas Health Science Center at...Completed
-
GWT-TUD GmbHTechnische Universität Dresden; University of Regensburg; Diakonissen Krankenhaus...CompletedType 2 Diabetes Mellitus | Subclinical InflammationGermany
-
GWT-TUD GmbHCompleted